MASSACHUSETTS STANDARD FORM FOR CHEMOTHERAPY AND SUPPORTIVE CARE PRIOR AUTHORIZATION REQUESTS*

Request Date:	equest Date: Treatment Start [Date:		□ S	tandard	□ Ex	pedited
<u> </u>									
l.									
Health Plan N	ame:								
Health Plan Pl	none:			He	alth Plan Fax:				
Member Info	rmation								
First:		8		Last:				MI:	
DOB:		Sex as	Sex assigned at birth: ☐ Male ☐ Female ☐ "X" or Intersex						
DOU.		1	-		emale 🗆 Tran			ender Ferna	le 🛘 Other
Height:					BSA (m²):				- ev
Diagnosis:					Stage (0-4 or recurrent):				
Insurance:				(ex: Medic					15
			*Information in attached office note Yes □						
*Tumor Histo	loev:						10		-
and gender st	t discriminate based				lity, religion, cres		ientation, or se	x (including g	ender identity
# Billing	Administrative	Route	e netrospec	Dose	Frequency	Cycles or	Billing	FDA	For single
Code/ CODE	THE RESIDENCE AND ADDRESS OF THE PARTY OF TH				and Schedule	Refills	Method (B=Buyand Bill or P = Pharmacy)	Approved for the Diagnosis?	use vials, is provider willing to dose round?
ī							□В□Р	DYDN	□Y □N □ Unknown
2							□В□Р	DYON	□Y □N □ Unknown
3		=					□В□Р	DYON	□Y □N □ Unknown
4							□В□Р	DYDN	□Y □N □ Unknown

HI	Supporting	g Care Drugs Request	od					(continued on next page
#	Billing	Administrative	Drug Name	Route	Dose	Frequency	Condition	Billing Method
	Code/ J CODE	Code				and Schedule	(ex: Nausea)	(B = Buy and Bill or P = Pharmacy)
1								□В□Р
2								□В□Р
3								□в□Р
4								□8 □P
lf E	Osteo SAs reques	thening agents or b on Bone Metastases ted, select indication: Chemotherapy Induc		djuvant Breast (Cancer	Disease (ACD)		
IV.	Provider a	and Place of Treatmen	t Information					
	dering Prov	rider:						
NPI			TIN #:	1_		DEA #:		
	ne:	1 /-e (-ee ->		Fax:				
		der: (if different)		TNA				
	NPI #. TIN #. Phone: Fax:							
		mants (if different)		Fax:				
	Place of Treatment: (if different) NPI #: TIN #:							
	Phone: Fax:							
Ad	dress of Tre	eatment Center:						
ls t	he patient	currently being treated	with the requested regimen(s	:)?	No 🗆 Ur	known		
Lin	e of Treatn	nent:						
WI	at therapid	es has the patient previ	ously tried?					
	•	1.1	umor mutations/biomarkers/gekers/genetic testing result has t	_			own	
			is this provider the only availab Tyes INO Unknown	le treating/serv	icing provid	er within a reas	sonable distanc	e that can provide this
			cer treatments from the reque	sting treating p	rovider? 🗆	Yes □ No	□ Unknown	
ls t	reating pro	vider in-network?	′es □ No □ Unknown					
Site	of Service	e: 🗆 Outpatient Hospi	tal 🗆 Home Infusion 🗆 O	ther				
Att	achments	Labs Imaging	☐ Chemo Orders ☐ Patho	ology 🗆 Progr	ess Notes			
Au	horized Re	epresentative:						
Pho	ne:		Fax:	Fax:				

V. Exceptions to Step Therapy Please complete the applicable section(s).						
mental harm to the member?	Iternative drug required under the step therapy protocol contraindicated, or will likely cause an adverse reaction in, or physical or harm to the member? Yes No oriefly describe details of contraindication, adverse reaction, or harm:					
	der the step therapy protocol expected to be ineffective based on the known clinical characteristics of the					
100	istics of the alternative drug regiment? Yes No					
If yes, briefly describe details of kn	own clinical characteristics of member and alternative drug regimen.					
	the alternative drug required under the step therapy protocol, or another alternative drug in the same ime mechanism of action, and such alternative drug was discontinued due to lack of efficacy or effectiveness,					
diminished effect, or an adverse ev	rent! ☐ Yes ☐ No					
If yes, please provide details for th	e previous trial:					
Drug Name:	Dates/duration of use:					
Did the member experience any o	of the following? Adverse reaction Inadequate response					
Briefly describe details of adverse r	eaction or inadequate response:					
Drug Name:	Dates/duration of use:					
Did the member experience any o	of the following? Adverse reaction Inadequate response					
Briefly describe details of adverse r	eaction or inadequate response:					
Is the member stable on the requi	ested prescription drug prescribed by the health care provider, and switching drugs will likely cause an adverse					
	narm to the member? \square Yes \square No					
1 '	e member's stability and the likely adverse reaction or physical or mental harm:					
	28					

Providers should consult the health plan's coverage policies, member benefits, and medical necessity guidelines to complete this form. Providers must attach any additional data required relevant to medical necessity criteria, including PROGRESS NOTES, CHEMO ORDERS, LABS, PATHOLOGY, AND IMAGING RESULTS WITH REQUEST.